The Role of CDK 4/6 Inhibitors in the Management of Breast Cancer

Topics covered in this activity include: development of endocrine resistance in breast cancer; significance of CDK inhibition; relevant clinical data.

Available credits: 0.75

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hormone receptor–positive (HR+) disease is the most commonly diagnosed subset of breast cancer. Although endocrine therapy is the cornerstone of treatment for patients with HR+ advanced breast cancer, not all cases respond to first-line endocrine therapy, and disease that does respond eventually relapses. Because endocrine therapy–resistant HR+ disease is a significant problem, new therapeutic strategies to enhance the efficacy of endocrine therapy are being studied. Several CDK 4/6 inhibitors have shown promising results in the treatment of breast cancer, particularly HR+, HER2-negative metastatic disease. However, clinicians may not be familiar with the mechanisms of CDK 4/6 inhibition and why it is relevant in the treatment of breast cancer. Similarly, clinicians may not be familiar with the efficacy and safety of approved and emerging CDK 4/6 inhibitors in the treatment of breast cancer that is resistant to endocrine therapy. 

    This Virtual Grand Rounds initiative is designed to close these knowledge gaps and provide clinicians with up-to-date information about approved and emerging therapies so that they can make informed choices regarding the management of breast cancer. Topics covered in this activity include the development of endocrine resistance in breast cancer; the significance of CDK inhibition; and the relevant clinical trial data about the efficacy and safety of CDK 4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the mechanisms of CDK inhibition and the rationale for its utility in breast cancer
    • Evaluate the efficacy of approved and emerging CDK inhibitors as an option for treating breast cancer that is resistant to endocrine therapy
    • Assess toxicity profiles associated with approved and emerging CDK 4/6 inhibitors for treating breast cancer
  • Target Audience

    This activity is intended for oncologists, pathologists, surgeons, nurses, and other healthcare professionals involved in the care and treatment of patients with HR+ breast cancer.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest
    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Richard S. Finn, MD

    Assistant Professor, Department of Medicine
    Division of Hematology/Oncology
    David Geffen School of Medicine
    Physician, Department of Surgery
    Dumont-UCLA Liver Cancer Center
    Co-Director, Signal Transduction and Therapeutics Program
    Jonsson Comprehensive Cancer Center at UCLA
    Los Angeles

    Consultant/Independent contractor fee paid to UCLA: Bayer Pharmaceuticals Corp.; Bristol-Myers Squibb Co.; Novartis Pharmaceuticals Corp.; Pfizer, Inc.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Andrea Funk has nothing to disclose. 
    • Laura Gilsdorf has nothing to disclose. 
    • Amanda Glazar, PhD has nothing to disclose. 
    • Linda Gracie-King, MS has nothing to disclose. 
    • Jocelyn Timko, BS has nothing to disclose. 
    • Isabelle Vacher has nothing to disclose. 
    • Ronald Viggiani, MD has nothing to disclose. 
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement

    Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Physician Credit Designation

    Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Instructions to Receive Credit

    In order to receive credit for this activity, during the period, 5/13/2016, through, 5/12/2017, participants must read the learning objectives and faculty disclosures, study the educational activity, and score a 75% or greater on the activity post-test. Your completed evaluation is requested.

    Fee Information & Refund/Cancellation Policy
    There is no fee for this educational activity.

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com 

  • Provider(s)/Educational Partner(s)

    This activity is provided by Global Education Group.

  • Commercial Support

    This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global)  and AXIS Medical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

NEW FEATURES: